We hypothesise however, that in luminal-type/ER+/LN− breast cancer, AREG expression downstream of ERα-CITED1 may be associated with an active ERα-coregulator complex that is more amenable to endocrine antagonism. The gene discussed is AREG; the disease is breast cancer.